NSD2 and benign neoplasm: To evaluate expression of NSD2 protein in human prostate cancer, we performed immunohistochemistry on a human prostate cancer tissue microarray (n = 100) comprised of benign tumors (n = 26), non-lethal prostate adenocarcinoma (n = 25), lethal castration-resistance adenocarcinomas (CRPC-Adeno; n = 31), and neuroendocrine prostate tumors (NEPC; n = 18) (Fig. 4d).